bepotastine (bepreve) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. It belongs to the second-generation piperidine chemical class. It is a mast cell stabilizer and suppresses the migration of eosinophils into inflamed tissues. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.   NCATS

Chemistry

  • SMILES: OC(=O)CCCN1CCC(CC1)O[C@@H](c2ccc(Cl)cc2)c3ccccn3
  • InChIKey: YWGDOWXRIALTES-NRFANRHFSA-N
  • Mol. Mass: 388.9
  • ALogP: 4.17
  • ChEMBL Molecules:
    bepotastine  
    bepotastine besylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$30.6990 - $46.3256
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bb | bepotastine | bepotastine besilate | bepotastine besylate | bepotastine salicylate | bepreve | betotastine | betotastine besilate | (s)-4-(4-((4-chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid monobenzenesulfonate | tau 284 | tau-284 | tau-284ds

Organizations (26)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (2)


 

Conjunctivitis, Allergic

Rhinitis, Allergic (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Allergy and Immunology (Phase 4)

Conjunctivitis, Allergic ()

Cough (Phase 4)

Dermatitis (Phase 3)

Healthy Volunteers (Phase 1)

Lung Diseases (Phase 1)

Pruritus (Phase 3)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 2)

Safety (Phase 1)

Urticaria (Phase 1)

Vision, Ocular (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue